Protagenic Therapeutics IncNASDAQ:PTIXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6070
- TODAY'S CHANGE (%)-0.0012 (-0.1973%)
- Bid / Lots0.6071/ 9
- Ask / Lots0.6602/ 2
- Open / Previous Close0.6385 / 0.6082
- Day Range
- 52 Week Range
- Volume26,715
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PTIX |
|---|---|---|
| 09:55 ET | 100 | 0.6385 |
| 09:57 ET | 100 | 0.6385 |
| 10:00 ET | 199 | 0.6385 |
| 10:08 ET | 600 | 0.6385 |
| 10:24 ET | 1894 | 0.6385 |
| 10:26 ET | 134 | 0.63 |
| 10:33 ET | 9890 | 0.607 |
| 10:38 ET | 300 | 0.607 |
| 10:42 ET | 1000 | 0.607828 |
| 10:44 ET | 100 | 0.607 |
| 10:56 ET | 316 | 0.61 |
| 12:19 ET | 100 | 0.619 |
| 01:40 ET | 100 | 0.607 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Protagenic Therapeutics Inc | 2.7M | -0.4x | --- |
Bone Biologics Corp | 2.7M | -0.1x | --- |
Galera Therapeutics Inc | 2.7M | -0.1x | --- |
Phio Pharmaceuticals Corp | 2.7M | -0.1x | --- |
Qualigen Therapeutics Inc | 2.7M | -0.1x | --- |
Biostax Corp | 2.9M | -1.7x | --- |
Company Information
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.
Contact Information
- Headquarters
- 149 FIFTH AVENUE, SUITE 500NEW YORK, NY, United States 10010
- Phone
- 212-994-8200
- Fax
- 302-636-5454
Executives
- Executive Chairman of the Board
- Garo Armen
- Chief Financial Officer
- Alexander Arrow
- Chief Operating Officer
- Andrew Slee
- Director, Chief Medical Officer
- Robert Stein
- Independent Director
- Khalil Barrage
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 4.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-1.45 |
Book Value | $0.83 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
